Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL39P28 (ribosomal protein L39 pseudogene 28) is a processed pseudogene in the human genome with homology to the functional ribosomal protein L39 gene (RPL39)[4][2]. Pseudogenes like RPL39P28 arise via retrotransposition events and do not produce functional proteins[2][4]. They are generally non-coding DNA that serves as evolutionary genomic remnants. RPL39P28 has no known biological function, therapeutic relevance, or disease association and is not considered a molecular target for drug development or biomarker use[4][2]. Note: The canonical "ribosomal protein L39" (RPL39) is a component of the cytoplasmic large (60S) ribosomal subunit, but RPL39P28 itself does not produce protein or participate in ribosome function[6][3][4]. The term "pseudogene" indicates the locus is a non-functional copy and not an active participant in cellular processes. Summary: RPL39P28 is a **pseudogene**, not a therapeutically targetable protein, enzyme, receptor, or transporter, and thus is not suitable for inclusion as a drug target or actionable biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L39 pseudogene 28 (RPL39P28).